Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

Sai Hong Ignatius Ou, Eunice L. Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W. Clark, D. Ross Camidge, Benjamin J. Solomon, Robert G. Maki, Yung Jue Bang, Dong Wan Kim, James Christensen, Weiwei Tan, Keith D. Wilner, Ravi Salgia, A. John Iafrate

Research output: Contribution to journalArticle

313 Citations (Scopus)

Abstract

Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

Original languageEnglish
Pages (from-to)942-946
Number of pages5
JournalJournal of Thoracic Oncology
Volume6
Issue number5
DOIs
StatePublished - 1 May 2011

Fingerprint

Epithelial-Mesenchymal Transition
Non-Small Cell Lung Carcinoma
anaplastic lymphoma kinase
crizotinib

Keywords

  • 18F-FDG PET/CT
  • Anaplastic lymphoma kinase (ALK) re-arranged NSCLC
  • Crizotinib (PF02341066)
  • De novo MET amplification NSCLC
  • MET polysomy
  • Non-small cell lung cancer

Cite this

Ou, Sai Hong Ignatius ; Kwak, Eunice L. ; Siwak-Tapp, Christina ; Dy, Joni ; Bergethon, Kristin ; Clark, Jeffrey W. ; Camidge, D. Ross ; Solomon, Benjamin J. ; Maki, Robert G. ; Bang, Yung Jue ; Kim, Dong Wan ; Christensen, James ; Tan, Weiwei ; Wilner, Keith D. ; Salgia, Ravi ; Iafrate, A. John. / Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 5. pp. 942-946.
@article{75dee6e05c784535a508d5ed83bfb4fe,
title = "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification",
abstract = "Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.",
keywords = "18F-FDG PET/CT, Anaplastic lymphoma kinase (ALK) re-arranged NSCLC, Crizotinib (PF02341066), De novo MET amplification NSCLC, MET polysomy, Non-small cell lung cancer",
author = "Ou, {Sai Hong Ignatius} and Kwak, {Eunice L.} and Christina Siwak-Tapp and Joni Dy and Kristin Bergethon and Clark, {Jeffrey W.} and Camidge, {D. Ross} and Solomon, {Benjamin J.} and Maki, {Robert G.} and Bang, {Yung Jue} and Kim, {Dong Wan} and James Christensen and Weiwei Tan and Wilner, {Keith D.} and Ravi Salgia and Iafrate, {A. John}",
year = "2011",
month = "5",
day = "1",
doi = "10.1097/JTO.0b013e31821528d3",
language = "English",
volume = "6",
pages = "942--946",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "5",

}

Ou, SHI, Kwak, EL, Siwak-Tapp, C, Dy, J, Bergethon, K, Clark, JW, Camidge, DR, Solomon, BJ, Maki, RG, Bang, YJ, Kim, DW, Christensen, J, Tan, W, Wilner, KD, Salgia, R & Iafrate, AJ 2011, 'Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification', Journal of Thoracic Oncology, vol. 6, no. 5, pp. 942-946. https://doi.org/10.1097/JTO.0b013e31821528d3

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. / Ou, Sai Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung Jue; Kim, Dong Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John.

In: Journal of Thoracic Oncology, Vol. 6, No. 5, 01.05.2011, p. 942-946.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

AU - Ou, Sai Hong Ignatius

AU - Kwak, Eunice L.

AU - Siwak-Tapp, Christina

AU - Dy, Joni

AU - Bergethon, Kristin

AU - Clark, Jeffrey W.

AU - Camidge, D. Ross

AU - Solomon, Benjamin J.

AU - Maki, Robert G.

AU - Bang, Yung Jue

AU - Kim, Dong Wan

AU - Christensen, James

AU - Tan, Weiwei

AU - Wilner, Keith D.

AU - Salgia, Ravi

AU - Iafrate, A. John

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

AB - Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

KW - 18F-FDG PET/CT

KW - Anaplastic lymphoma kinase (ALK) re-arranged NSCLC

KW - Crizotinib (PF02341066)

KW - De novo MET amplification NSCLC

KW - MET polysomy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=79955458487&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31821528d3

DO - 10.1097/JTO.0b013e31821528d3

M3 - Article

C2 - 21623265

AN - SCOPUS:79955458487

VL - 6

SP - 942

EP - 946

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 5

ER -